AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
CABOTEGRAVIR SODIUM
4 registrations across 3 African markets— 4 active
Markets with CABOTEGRAVIR SODIUM
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Apretude Tablets Film-Coated Tablet | 🇰🇪Kenya | GlaxoSmithKline Pharmaceutical Kenya Limited | active | Jul 2029 |
| APRETUDE PROLONGED RELEASE SUSPENSION FOR INJECTION Prolonged release suspension for injection | 🇷🇼Rwanda | GLAXO OPERATIONS UK LIMITED | active | Jul 2029 |
| APRETUDE 30mg Tablet, Filmcoated | 🇿🇲Zambia | GlaxoSmithKline South Africa (Pty) Ltd | active | Sept 2028 |
| APRETUDE 600mg/3ml Suspension for Injection | 🇿🇲Zambia | GlaxoSmithKline South Africa (Pty) Ltd | active | Sept 2028 |
CABOTEGRAVIR SODIUM in Africa — Regulatory Overview
CABOTEGRAVIR SODIUM is registered across 3 African markets with 4 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Zambia, Kenya, Rwanda. AfricaRegulatory refreshes this data daily from official government sources.
Of the 4 registrations, 4 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.